QUARTET USA (ClinicalTrials.gov Identifier: NCT03640312) is a phase II randomized trial testing the effect of a four-drug, quarter-dose blood pressure lowering combination among individuals with hypertension in federally qualified health centers in Chicago as part of the global QUARTET program (trial ongoing in Australia and in development in The Netherlands and Japan). This trial represents a reverse innovation of using fixed-dose combination, or polypill, therapy for cardiovascular disease prevention within a U.S. population that bears one of the highest burdens of hypertension-related illness in the world.
National Heart, Lung, and Blood Institute (R61 HL139852)
Northwestern Faculty and Staff
Co-PIs Mark Huffman, MD, MPH and Jody D Ciolino, PhD; Abigail Baldridge, MS; Namratha R Kandula, MD, MPH; Donald M Lloyd-Jones, MD, ScM; Stephen D Persell, MD, MPH; James Paparello, MD; Swapna Dave, MPH, PMP, MBBS; Sadiya Khan, MD, MS; Mianzhao Guo
Danielle Lazar, Jairo Mejia, Linda Rosul, Hiba Abbas, Edgar Pizarro, Access Community Health Network; Clara Chow, University of Sydney/Westmead Applied Research Centre; Anthony Rodgers and Emily Atkins, The George Institute for Global Health; Sharp; George Clinical
Chow CK, Thakkar J, Bennett A, Hillis G, Burke M, Usherwood T, Vo K, Rogers K, Atkins E, Webster R, Chou M, Dehbi HM, Salam A, Patel A, Neal B, Peiris D, Krum H, Chalmers J, Nelson M, Reid CM, Woodward M, Hilmer S, Thom S, Rodgers A. Quarter-dose quadruple combination therapy for initial treatment of hypertension:placebo-controlled, crossover, randomised trial and systematic review. Lancet. 2017 Mar 11;389(10073):1035-1042. doi: 10.1016/S0140-6736(17)30260-X.